• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

脱氢酶/还原酶2（DHRS2）在多种肿瘤中的辅助诊断及预后价值

Auxiliary Diagnosis and Prognostic Value of Dehydrogenase/Reductase 2 (DHRS2) in Various Tumors.

作者信息

An Zhongwu, Bo Weibo, Qin Jibao, Jiang Ling, Jiang Jie

机构信息

Clinical Laboratory, The Affiliated Lianyungang Oriental Hospital, Xuzhou Medical University, Jiang Su, China.

Department of Pharmacy, The Affiliated Lianyungang Oriental Hospital, Xuzhou Medical University, Jiang Su, China.

出版信息

Iran J Public Health. 2023 Jun;52(6):1150-1160. doi: 10.18502/ijph.v52i6.12957.

DOI:10.18502/ijph.v52i6.12957
PMID:37484140
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10362825/
Abstract

BACKGROUND

As the most convenient and commonly used for clinical diagnosis, cancer biomarker has been widely used in the auxiliary diagnosis of tumors, the observation of curative effect, the judgment of prognosis, and the monitoring of the disease.

METHODS

Pan-cancer analysis was used to validate the value of Dehydrogenase/Reductase 2 (DHRS2) as a tumor prognostic marker in various tumors. The relationship of DHRS2 to TMB and MSI was used to explain the effect of DHRS2 on genomic instability. Online cbioportal was used to analyze DHRS2 mutations in tumors. Finally, 33 clinical tumor samples were collected in 2021 who were enrolled into the Affiliated Lianyun-gang Oriental Hospital of Xuzhou Medical University, to verify the expression and diagnostic prognostic value of DHRS2.

RESULTS

The expression of DHRS2 was up-regulated in a variety of tumors and had adverse effects on the overall survival, disease-free interval, and progression-free interval of tumor patients. DHRS2 was associated with tumor genome instability, confirming that DHRS2 was correlated with tumorigenesis. In addition, DHRS2 had different mutation sites in various tumors. DHRS2 was up-regulated and was a poor prognosis biomarker in clinical tumor samples.

CONCLUSION

DHRS2 was aberrantly expressed in tumors and has diagnostic prognostic value.

摘要

背景

癌症生物标志物作为临床诊断中最便捷且常用的指标，已广泛应用于肿瘤的辅助诊断、疗效观察、预后判断及病情监测。

方法

采用泛癌分析来验证脱氢酶/还原酶2（DHRS2）作为多种肿瘤预后标志物的价值。利用DHRS2与肿瘤突变负荷（TMB）及微卫星高度不稳定（MSI）的关系来解释DHRS2对基因组不稳定的影响。通过在线cbioportal分析肿瘤中DHRS2的突变情况。最后，收集了2021年徐州医科大学附属连云港东方医院收治的33例临床肿瘤样本，以验证DHRS2的表达及诊断预后价值。

结果

DHRS2在多种肿瘤中表达上调，对肿瘤患者的总生存期、无病间期和无进展间期均有不良影响。DHRS2与肿瘤基因组不稳定相关，证实DHRS2与肿瘤发生有关。此外，DHRS2在不同肿瘤中有不同的突变位点。在临床肿瘤样本中，DHRS2表达上调且是预后不良的生物标志物。

结论

DHRS2在肿瘤中异常表达，具有诊断预后价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a5a/10362825/aff1d77bcf81/IJPH-52-1150-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a5a/10362825/0c9419a2edf9/IJPH-52-1150-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a5a/10362825/d1b062e0b184/IJPH-52-1150-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a5a/10362825/1a2fbdcee7aa/IJPH-52-1150-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a5a/10362825/6c1a326e3b59/IJPH-52-1150-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a5a/10362825/9dd3bd79a52d/IJPH-52-1150-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a5a/10362825/c3d4fd7f85a4/IJPH-52-1150-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a5a/10362825/aff1d77bcf81/IJPH-52-1150-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a5a/10362825/0c9419a2edf9/IJPH-52-1150-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a5a/10362825/d1b062e0b184/IJPH-52-1150-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a5a/10362825/1a2fbdcee7aa/IJPH-52-1150-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a5a/10362825/6c1a326e3b59/IJPH-52-1150-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a5a/10362825/9dd3bd79a52d/IJPH-52-1150-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a5a/10362825/c3d4fd7f85a4/IJPH-52-1150-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a5a/10362825/aff1d77bcf81/IJPH-52-1150-g007.jpg

相似文献

1
Auxiliary Diagnosis and Prognostic Value of Dehydrogenase/Reductase 2 (DHRS2) in Various Tumors.脱氢酶/还原酶2（DHRS2）在多种肿瘤中的辅助诊断及预后价值
Iran J Public Health. 2023 Jun;52(6):1150-1160. doi: 10.18502/ijph.v52i6.12957.
2
Characterization of the dehydrogenase-reductase DHRS2 and its involvement in histone deacetylase inhibition in urological malignancies.鉴定脱氢酶还原酶 DHRS2 及其在泌尿系统恶性肿瘤中组蛋白去乙酰化酶抑制作用的关系。
Exp Cell Res. 2024 Jun 1;439(1):114055. doi: 10.1016/j.yexcr.2024.114055. Epub 2024 May 3.
3
STAMBPL1 promotes the progression of lung adenocarcinoma by inhibiting DHRS2 expression.STAMBPL1通过抑制DHRS2表达促进肺腺癌进展。
Transl Oncol. 2023 Sep;35:101728. doi: 10.1016/j.tranon.2023.101728. Epub 2023 Jun 30.
4
DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma.DHRS2 抑制食管鳞状细胞癌中的细胞生长和迁移。
Oncogene. 2018 Feb 22;37(8):1086-1094. doi: 10.1038/onc.2017.383. Epub 2017 Nov 6.
5
Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer.DHRS2 表达降低与卵巢癌中 HDACi 耐药和不良预后相关。
Epigenetics. 2020 Jan-Feb;15(1-2):122-133. doi: 10.1080/15592294.2019.1656155. Epub 2019 Sep 3.
6
Emerging roles of dehydrogenase/reductase member 2 (DHRS2) in the pathology of disease.脱氢酶/还原酶成员 2（DHRS2）在疾病发病机制中的新兴作用。
Eur J Pharmacol. 2021 May 5;898:173972. doi: 10.1016/j.ejphar.2021.173972. Epub 2021 Feb 27.
7
DHRS2 mediates cell growth inhibition induced by Trichothecin in nasopharyngeal carcinoma.DHRS2 介导了脱氧瓜萎镰菌醇诱导的鼻咽癌细胞生长抑制。
J Exp Clin Cancer Res. 2019 Jul 10;38(1):300. doi: 10.1186/s13046-019-1301-1.
8
A potential immunotherapeutic and prognostic biomarker for multiple tumors including glioma: SHOX2.作为一种潜在的免疫治疗和预后生物标志物，SHOX2 可用于多种肿瘤，包括神经胶质瘤。
Hereditas. 2023 May 11;160(1):21. doi: 10.1186/s41065-023-00279-8.
9
Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.系统泛癌症分析鉴定 TREM2 为一种免疫和预后生物标志物。
Front Immunol. 2021 Feb 17;12:646523. doi: 10.3389/fimmu.2021.646523. eCollection 2021.
10
Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.泛癌分析 PDIA3：鉴定其为肿瘤预后和免疫治疗的潜在生物标志物。
Oxid Med Cell Longev. 2022 Aug 22;2022:9614819. doi: 10.1155/2022/9614819. eCollection 2022.

本文引用的文献

1
Global cancer research in the post-pandemic world.疫情后世界的全球癌症研究。
Lancet Oncol. 2021 Dec;22(12):1652-1654. doi: 10.1016/S1470-2045(21)00602-1.
2
The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers.2020 年欧洲癌症负担：40 个国家和 25 种主要癌症的发病率和死亡率估计。
Eur J Cancer. 2021 Nov;157:308-347. doi: 10.1016/j.ejca.2021.07.039. Epub 2021 Sep 21.
3
Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy.
谷胱甘肽耗竭在癌症治疗中的应用：增强基于 ROS 的治疗、铁死亡和化疗。
Biomaterials. 2021 Oct;277:121110. doi: 10.1016/j.biomaterials.2021.121110. Epub 2021 Aug 30.
4
Rag GTPases suppress PRL-3 degradation and predict poor clinical diagnosis of cancer patients with low PRL-3 mRNA expression.Rag GTP酶抑制PRL-3的降解，并预示PRL-3 mRNA低表达的癌症患者临床诊断不佳。
Biochem Biophys Res Commun. 2021 Oct 22;576:108-116. doi: 10.1016/j.bbrc.2021.08.090. Epub 2021 Aug 31.
5
Integration of quantitative imaging biomarkers in clinical trials for MR-guided radiotherapy: Conceptual guidance for multicentre studies from the MR-Linac Consortium Imaging Biomarker Working Group.定量成像生物标志物在磁共振引导放射治疗临床试验中的整合：MR-Linac 联盟成像生物标志物工作组对多中心研究的概念性指导。
Eur J Cancer. 2021 Aug;153:64-71. doi: 10.1016/j.ejca.2021.04.041. Epub 2021 Jun 15.
6
Conserved pan-cancer microenvironment subtypes predict response to immunotherapy.泛癌种保守的微环境亚型可预测免疫治疗的反应。
Cancer Cell. 2021 Jun 14;39(6):845-865.e7. doi: 10.1016/j.ccell.2021.04.014. Epub 2021 May 20.
7
Type IV collagen as a potential biomarker of metastatic breast cancer.IV 型胶原作为转移性乳腺癌的潜在生物标志物。
Clin Exp Metastasis. 2021 Apr;38(2):175-185. doi: 10.1007/s10585-021-10082-2. Epub 2021 Mar 3.
8
Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer.CA125 在卵巢癌的诊断、预测和肿瘤发生中的作用。
Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188503. doi: 10.1016/j.bbcan.2021.188503. Epub 2021 Jan 7.
9
Increased serum CA125 II, but not CEA，CA19-9，AFP or CA72-4 in colon cancer compared to rectal cancer.与直肠癌相比，结肠癌患者血清CA125 II升高，而CEA、CA19-9、AFP或CA72-4未升高。
Br J Biomed Sci. 2021 Oct;78(4):218-220. doi: 10.1080/09674845.2020.1868685. Epub 2021 Feb 12.
10
Prognostic value and immunological role of PDCD1 gene in pan-cancer.PDCD1 基因在泛癌中的预后价值和免疫作用。
Int Immunopharmacol. 2020 Dec;89(Pt B):107080. doi: 10.1016/j.intimp.2020.107080. Epub 2020 Oct 15.